Русский / English
Enter the query
Petrovax to Test Polyoxidonium for Covid-19 Treatment in an International Clinical Trial
Polyoxidonium (azoximer bromide) — the Russian original drug produced by Petrovax- was approved by the Ministry of Health of the Russian Federation for conducting an international clinical trial for the treatment of COVID-19.

The trial of the drug is carried out in accordance with the WHO Protocol. Concurrently, a clinical trial application for Polyoxidonium in COVID-19 patients is being reviewed by the French Ministry of Health. An application for trials in Slovakia is underway. Petrovax is also negotiating with regulators potential studies in other countries.
Russian clinical centers in Moscow, Nizhny Novgorod, Orenburg and Yaroslavl will test Polyoxidonium on 454 patients as well. The goal is to evaluate the efficacy and safety of Polyoxidonium in adults (men and women) aged 18 to 85 years with COVID-19. The first results are expected in June.

The existing studies on Polyoxidonium in patients with infectious diseases show that the drug can potentially be effective in the treatment of patients with SARS-CoV-2. First successful treatments of COVID-19 patients using Polyoxidonium therapy were achieved in Slovakia. Following this experience, the drug was included in the clinical recommendations of the country for the treatment of patients with COVID-19.

More information is available at